USANA Health Sciences, Inc. (NYSE:USNA) COO Walter Noot Sells 6,291 Shares

USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) COO Walter Noot sold 6,291 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $30.29, for a total value of $190,554.39. The sale was disclosed in a filing with the SEC, which is available through this link.

USANA Health Sciences Stock Down 2.2%

Shares of NYSE USNA traded down $0.67 during midday trading on Monday, reaching $29.20. 133,341 shares of the company's stock traded hands, compared to its average volume of 133,620. The company has a market cap of $543.79 million, a price-to-earnings ratio of 10.32, a P/E/G ratio of 0.93 and a beta of 0.60. USANA Health Sciences, Inc. has a one year low of $23.10 and a one year high of $49.16. The stock's 50 day simple moving average is $27.39 and its 200-day simple moving average is $31.71.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.70 by $0.03. The business had revenue of $249.54 million for the quarter, compared to the consensus estimate of $243.08 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. During the same period last year, the business posted $0.86 EPS. Equities analysts predict that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on USNA. Sidoti downgraded shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th. Wall Street Zen raised USANA Health Sciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Finally, DA Davidson dropped their price target on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, February 27th.

Institutional Investors Weigh In On USANA Health Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. grew its stake in USANA Health Sciences by 339.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock worth $27,000 after buying an additional 771 shares during the last quarter. R Squared Ltd acquired a new position in shares of USANA Health Sciences during the fourth quarter valued at about $28,000. Versant Capital Management Inc raised its position in shares of USANA Health Sciences by 542.5% in the 1st quarter. Versant Capital Management Inc now owns 1,150 shares of the company's stock valued at $31,000 after purchasing an additional 971 shares during the last quarter. Parallel Advisors LLC boosted its stake in USANA Health Sciences by 8,141.2% in the 1st quarter. Parallel Advisors LLC now owns 1,401 shares of the company's stock worth $38,000 after purchasing an additional 1,384 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in USANA Health Sciences during the 4th quarter worth approximately $83,000. Hedge funds and other institutional investors own 54.25% of the company's stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.